Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Lirafugratinib |
| Synonyms | |
| Therapy Description |
RLY-4008 binds to and inhibits FGFR2, selectively targeting primary oncogenic FGFR2 mutations and leads to decreased FGFR2-dependent signaling, potentially resulting in inhibition of tumor cell proliferation (NCI Drug Dictionary; Journal of Clinical Oncology 39, no. 15_suppl). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lirafugratinib | RLY4008|RLY 4008|RLY-4008 | FGFR2 Inhibitor 23 | Lirafugratinib binds to and inhibits FGFR2, selectively targeting primary oncogenic FGFR2 mutations and leads to decreased FGFR2-dependent signaling, potentially resulting in inhibition of tumor cell proliferation (NCI Drug Dictionary; Journal of Clinical Oncology 39, no. 15_suppl). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 Y375C | salivary gland carcinoma | predicted - sensitive | Lirafugratinib | Case Reports/Case Series | Actionable | In a Phase I/II trial (ReFocus), Lirafugratinib treatment resulted in a partial response with near complete resolution of liver metastases, and regression of lung and adrenal metastases in a patient with metastatic carcinoma of the right parotid salivary gland harboring FGFR2 Y375C (PMID: 37270847; NCT04526106). | 37270847 |
| FGFR2 N549K | endometrial cancer | predicted - sensitive | Lirafugratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lirafugratinib treatment led to tumor regression in a cell line xenograft model of endometrial cancer harboring FGFR2 N549K (Cancer Res 2021;81(13_Suppl):Abstract nr 1455). | detail... |
| FGFR2 amp | colorectal adenocarcinoma | sensitive | Lirafugratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lirafugratinib inhibited proliferation of a colorectal adenocarcinoma cell line with FGFR2 amplification in culture (PMID: 37270847). | 37270847 |
| FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564L (PMID: 37270847). | 37270847 |
| FGFR2 K310R FGFR2 N549K | endometrial adenocarcinoma | sensitive | Lirafugratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lirafugratinib inhibited proliferation of an endometrial adenocarcinoma cell line harboring FGFR2 N549K and FGFR K310R in culture, and led to tumor regression in a cell line xenograft model (PMID: 37270847). | 37270847 |
| FGFR2 E565A | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 E565A (PMID: 37270847). | 37270847 |
| FGFR2 C383R | breast cancer | sensitive | Lirafugratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lirafugratinib inhibited proliferation of a breast carcinoma cell line harboring FGFR2 C383R in culture (PMID: 37270847). | 37270847 |
| FGFR2 L617V | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 L617V (PMID: 37270847). | 37270847 |
| FGFR2 K641N | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 K641N (PMID: 37270847). | 37270847 |
| FGFR2 fusion | cholangiocarcinoma | predicted - sensitive | Lirafugratinib | Phase Ib/II | Actionable | In a Phase I/II trial (ReFocus), Lirafugratinib treatment resulted in radiographic tumor reductions in 64% (74/116) and partial responses/stable disease in 72% (83/116) of patients with advanced solid tumors harboring FGFR2 alterations, and an objective response rate of 52% (13/25) and a disease control rate of 88% (22/25) in FGFR inhibitor-naive cholangiocarcinoma patients harboring FGFR2 fusions or rearrangements (J Clin Oncol 41, 2023 (suppl 16; abstr 4009); NCT04526106). | detail... |
| FGFR2 C383R FGFR2 N550D | intrahepatic cholangiocarcinoma | sensitive | Lirafugratinib | Preclinical - Pdx | Actionable | In a preclinical study, Lirafugratinib inhibited tumor growth in a patient-derived xenograft (PDX) model of intrahepatic cholangiocarcinoma harboring FGFR2 C383R and FGFR2 N550D (PMID: 39226398). | 39226398 |
| FGFR2 V564F | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564F (PMID: 37270847). | 37270847 |
| FGFR2 N549D | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 N549D (PMID: 37270847). | 37270847 |
| FGFR2 K659M | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 K659M (PMID: 37270847). | 37270847 |
| FGFR2 amp | stomach cancer | sensitive | Lirafugratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lirafugratinib treatment inhibited proliferation of gastric carcinoma cell lines with an FGFR2 amplification in culture, and led to tumor regression in a cell line xenograft model (PMID: 37270847). | 37270847 |
| FGFR2 N549H | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 N549H (PMID: 37270847). | 37270847 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04526106 | Phase I | Lirafugratinib | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 4 |
CKB BOOST